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Abstract
Purpose Metarrestin is a first-in-class small molecule clinical candidate capable of disrupting the perinucleolar compart-
ment, a subnuclear structure unique to metastatic cancer cells. This study aims to define the pharmacokinetic (PK) profile 
of metarrestin and the pharmacokinetic/pharmacodynamic relationship of metarrestin-regulated markers.
Methods PK studies included the administration of single or multiple dose of metarrestin at 3, 10, or 25 mg/kg via intrave-
nous (IV) injection, gavage (PO) or with chow to wild-type C57BL/6 mice and KPC mice bearing autochthonous pancreatic 
tumors. Metarrestin concentrations were analyzed by UPLC–MS/MS. Pharmacodynamic assays included mRNA expression 
profiling by RNA-seq and qRT-PCR for KPC mice.
Results Metarrestin had a moderate plasma clearance of 48 mL/min/kg and a large volume of distribution of 17 L/kg at 3 mg/
kg IV in C57BL/6 mice. The oral bioavailability after single-dose (SD) treatment was > 80%. In KPC mice treated with SD 
25 mg/kg PO, plasma AUC 0–∞ of 14400 ng h/mL, Cmax of 810 ng/mL and half-life (t1/2) of 8.5 h were observed. At 24 h after 
SD of 25 mg/kg PO, the intratumor concentration of metarrestin was high with a mean value of 6.2 µg/g tissue (or 13 µM), 
well above the cell-based  IC50 of 0.4 µM. At multiple dose (MD) 25 mg/kg/day PO in KPC mice, mean tissue/plasma AUC 
0–24h ratio for tumor, spleen and liver was 37, 30 and 31, respectively. There was a good linear relationship of dosage to AUC 
0–24h and  C24h. AUC 0–24h MD to AUC 0–24h SD ratios ranged from two for liver to five for tumor indicating additional accu-
mulation in tumors. Dose-dependent normalization of FOXA1 and FOXO6 mRNA expression was observed in KPC tumors.
Conclusions Metarrestin is an effective therapeutic candidate with a favorable PK profile achieving excellent intratumor 
tissue levels in a disease with known poor drug delivery.
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HPLC  High-performance liquid 
chromatography
1H-NMR  Proton nuclear magnetic resonance
HP-β-CD  (2-Hydroxylpropyl)-beta-cyclodextrin
HQC  High quality-control
IC50  Inhibitory concentration 50
IND  Investigational new drug
IV  Intravenous
K2EDTA  Dipotassium ethylenediaminetetraacetic 
acid
LC–MS/MS  Liquid chromatography–tandem mass 
spectrometry
LLOQ  Lower limit of quantitation
LOQ  Low quality-control
LTQ  Linear trap quadrupole
MD  Multiple dose
MQC  Middle quality-control
NOD/IL2  Nonobese diabetic/interleukin-2
NSG  NOD scid gamma
OCT  Optimal cutting temperature compound
PD  Pharmacodynamic
PK  Pharmacokinetics
PNC  Perinucleolar compartment
PO  Per os
Ppm  Parts per million
PTB1  Polypyrimidine tract-binding protein 1
QC  Quality control
RIN  RNA integrity numbers
RPMI  Roswell Park Memorial Institute Media
S.D.  Standard deviation
SD  Single dose
SPARC  Secreted protein acidic and rich in 
cysteine
TFA  Trifluoroacetic acid
UPLC–MS/MS  Ultra-performance liquid chromatogra-
phy–tandem mass spectrometry
Vdss  Steady-state volume of distribution
Introduction
Despite metastatic disease dissemination being the main 
cause of cancer-related mortality, there is a dispropor-
tionate paucity of successful drug development efforts 
selectively targeting metastasis [1–3]. Although there 
are various well characterized key processes and signal 
transduction pathways involved in metastatic colonization 
such as transcriptional programs induced by snail fam-
ily transcriptional repressor 1 (SNAI1), inhibitor of DNA 
binding 1 (ID1), GATA-binding protein (GATA3), EMT, 
upregulated autocrine interleukin-6 (IL-6)-signal trans-
ducer and activator of transcription 3 (STAT3) signaling, 
or dysregulation of exosome formation and expression 
of various non-coding RNAs (reviewed in Steeg), these 
perturbations are either difficult to target, have redundant 
parallel signaling routes, are essential for normal tissue 
homeostasis, or are not selective for the evolved, meta-
static disease stage [4].
The perinucleolar compartment (PNC) is a small sub-
nuclear organelle located adjacent to the nucleolus [5–7]. 
The PNC is enriched with RNA polymerase III transcripts, 
small nuclear RNAs, and RNA binding proteins [7–9]. 
Importantly, the PNC is unique to tumor cells from solid 
organ cancers [10]. PNC prevalence (the presence of one or 
more PNC structures per cell) correlates in various in vitro 
and in vivo cancer models, as well as in patient-derived clin-
ical samples with the evolvement of malignant progression 
[10]. In correlative tissue studies of clinical samples from 
patients with breast, colon, and ovarian cancer PNC preva-
lence is both a strong predictive and prognostic marker of 
overall patients clinical outcome including overall survival 
[7, 11, 12]. Thus, the PNC is an attractive marker for drug 




anol; Fig. 1b, MW: 474.6) was discovered from a high 
content drug screen of a > 140,000 compound library 
by selecting compounds via their ability to disassemble 
fluorescence-labelled PNC structures measured by high-
throughput immunofluorescence microscopy imaging [13, 
14]. To uncouple the PNC disassembling activity from 
the cytotoxic mode of action of DNA intercalators and 
topoisomerase I and II inhibitors previously known to 
disassemble the PNC, hits of the primary screen were re-
screened, and excluded, via assays measuring cytotoxicity, 
apoptosis, or DNA intercalation displacement assays to 
arrive, after medicinal chemistry optimization, at metar-
restin (ML-246) [14]. Metarrestin disassembles PNCs at 
submicromolar concentrations in solid organ cancer cell 
lines, suppresses metastasis formation, and extends sur-
vival in preclinical xenotransplantation models [15]. No 
toxicities have been observed at efficacious doses ranging 
between 5 and 25 mg/kg in mice [14, 15]. Thermostability 
and siRNA phenocopy studies have identified isoform 2 
of the translation elongation factor eEF1A (eEF1A2) as a 
putative molecular target [15]. eEF1A2 is upregulated in 
pancreas cancer and other solid organ cancers compared 
to normal tissues, is overexpressed in metastatic disease 
sites (lymph nodes, distant organ metastasis) compared to 
primary tumors, and elevated expression levels are asso-
ciated with poor survival outcome [16–20]. eEF1A2 is 
involved in many essential processes of the cell regulation 
including protein synthesis, maintenance of cytoskeletal 
architecture, or nuclear export regulation [21–24]. While 
some pro-oncogenic perturbations like upregulation of 
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metalloproteinases governed by eEF1A2 or reduction of 
oxidative stress have been described, the exact mechanism 
of action as a bone fide cancer gene remains to be identi-
fied [25, 26].
To date, no comprehensive plasma, tissue, and tumor 
PK studies of this first-in-class compound have been 
reported so far. Here, we chose the Ras-driven, autochtho-
nous KPC model to study PK and PK/PD relationships of 
metarrestin in pancreas cancer, a murine tumor model that 
recapitulates the challenges of poor drug delivery, a con-
sequence of dense desmoplastic stroma and poor vascu-
larization, observed in human pancreatic cancers [27–30]. 
The unique microenvironment in pancreatic cancer is well 
recognized to impede intratumoral drug penetration via 
perfusion and the inability to deliver efficacious concen-
trations to tumor cells limits efficacy of systemic chemo-
therapies. We correlated intratumor metarrestin exposure 
levels with administered dose levels, as well as markers 
impacted by metarrestin identified via differential gene 
expression and gene response patterns in KPC tumors 
vs matched normal, uninvolved pancreata which do not 
harbor PNCs. The knowledge of metarrestin PK proper-
ties at different exposure levels and the identification of 
dynamic biomarkers correlated with metarrestin exposure 
levels may drive the design of future relevant preclinical 






cyclohexanol] was manufactured in-house using the pre-
viously described 4-step synthesis sequence [14]. Purity 
(> 98%) was determined by LC-MS/MS and 1H-NMR 
analysis as previously reported [14]. To enhance bioavail-
ability, the drug was micronized to particles of uniform 
small size with greater surface area using a technique pro-
prietary to Crititech Inc. (Lawrence, Kansas) [31]. In brief, 
the drug substance was dissolved in organic solvent dichlo-
romethane and precipitated using compressed super criti-
cal carbon dioxide as the anti-solvent. The produced mate-
rial had 90% particles with a diameter less than 1.131 µm 
with a mean diameter of 0.829 µm (Suppl. Figure 1). The 
technique of attaining homogeneous particle size distribu-
tion by rapid change in solvent followed previous prece-
dents to improve exposure in rodents [32–34]. Micronized 
metarrestin was used to formulate metarrestin-containing 
chow in NIH Haslan 31 rodent diet at 70 ppm or 170 ppm 
as equivalents of 10 mg/kg and 25 mg/kg daily doses based 
on 15–18% of life weight daily food consumption.
Fig. 1  PNC disassembly as 
anti-metastasis therapy. a The 
PNC, not present in normal 
and pre-invasive disease stages, 
reflects the malignant phenotype 
at the late stage of the malignant 
transformation process, and thus 
can be a marker to select drugs 
that target processes selec-
tive for metastasis. b Chemi-
cal structure of metarrestin 
(ML-246). c Mean (± S.D.) 
metarrestin concentration–time 
profiles in C57BL/6 mice after 
single IV and PO administration 
(n = 3 per time point)
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Cell lines
Murine pancreatic KPC cancer cell lines were a kind gift 
of Ken Olive (Columbia University), and human pancreatic 
cancer lines FA-6 and PK-59 were generously provided by 
Nick Lemoine (Barts Cancer Institute, London, UK) and 
the RIKEN BRC cell bank (cellbank@brc.riken.jp). All cell 
lines were grown in RPMI supplemented with 10% fetal 
bovine serum (HyClone™, FisherScientific, Hampton, NH), 
2 mM glutamine (Gibco Thermo Fisher, Waltham, MA), 
and 100 U penicillin/0.1 mg/mL streptomycin (Gibco) under 
5%  CO2.
Animals
6–8-week old male C57BL/6 mice were purchased from 
Mouse Repository, Frederick National Laboratories for 
Cancer Research (FNLCR, Frederick, MD) or Charles River 
Laboratory (Frederick, MD). KrasLSL-G12D/+;Trp53LSL-
R172H/+;Pdx-1-Cre (KPC) mice were bred as described 
previously [27]. All animal protocols were reviewed and 
approved by the Institute of Animal Care and Use Com-
mittee (IACUC) of their respective institutes, and studies 
were conducted in compliance with institutional animal use 
guidelines.
KPC mice were enrolled into PK studies when palpation 
followed by ultrasound examination within 24 h revealed 
1 or 2 tumors with a combined volume of 100–250 mm3. 
Animals with three or more tumors per organ, pancreatic 
cysts or cystic tumors, signs of intestinal, pancreatic or gall 
bladder duct occlusions, or otherwise moribund/showing 
signs of dilapidation were excluded. Mice were randomized 
into treatment groups using their tumor volume and loca-
tion inside pancreas, animal age, gender, and weight by an 
unbiased covariate randomization.
Pharmacokinetic and pharmacodynamic studies 
in mice
For pharmacokinetic studies, metarrestin solutions prepared 
in 30% PEG-400 and 70% (20% w:v HP-β-CD in water) 
solution were administered to C57BL/6 mice at 3 mg/kg IV 
via tail vein injection, or 3 and 10 mg/kg orally via gavage. 
KPC mice were additionally treated with 25 mg/kg PO via 
gavage. The dosing volume was 3 mL/kg for IV route and 
10 mL/kg for PO route. Dosing solutions were prepared on 
the day of administration. Blood samples were collected at 
10, 20 min, 1, 2, 4, 7 and 24 h after 3 mg/kg IV administra-
tion. After oral administration of 3 and 10 mg/kg in C57BL6 
mice, blood and liver samples were collected at 10 min, 0.5, 
1, 2, 3, 5, 7, 9 and 24 h post dosing (n = 3 per time point). In 
KPC mice, blood, pancreatic tumor, spleen and liver samples 
were collected at 1, 2, 3, 6, 9, 12 and 24 h after 25 mg/kg 
PO administration.
For the assessment of multiple dose (MD) pharmacoki-
netics, KPC mice were treated with daily PO administration 
of 25 mg/kg metarrestin for 14 days. Plasma (100–300 µL), 
pancreatic tumors, spleen and liver samples were collected at 
0, 3, 6, 9, 12, 15, 24 and 48 h after last dose from three mice 
at each time point. Daily dosing was carried for 14 days, 
with the last dose administered at 9:00 a.m. on Day 14. To 
assess the steady-state concentration of metarrestin in KPC 
mice, animals were treated with drug-formulated chow for 
14 days. To control for daily cycle changes in feeding behav-
ior, 9:00 a.m. on day 0 was designated as the study start 
time, and 9:00 a.m. on Day 14 was designated as the 0 h time 
point for sample collection. Blood, pancreatic tumor, spleen 
and liver tissue were collected at 0, 3, 6, 9, 12, 15, and 24 h 
from three mice at each time point while the animals were 
continuously fed with metarrestin-formulated chow on Day 
14. Additional controls included mice with a matched drug-
free diet, with blood and tissue samples collected at the ini-
tial (t = 0) and two intermediate (t = 9 h, t = 24 h) time points.
Blood samples were collected in K2EDTA tubes and 
plasma was harvested after centrifugation at 3000 rpm for 
10 min. Tissue samples were weighed and flash-frozen for 
PK and PD mRNA expression analyses, embedded into OCT 
blocks for PNC determination and processed into FFPE 
blocks for histopathology assessment. All PK samples were 
stored at − 80 °C until analysis.
Quantitative metarrestin analysis: UPLC‑MS/MS
An ultra-performance liquid chromatography–tandem mass 
spectrometry (UPLC–MS/MS) method was developed to 
determine metarrestin concentrations in plasma and tissue 
samples. Mass spectrometric analysis was performed on a 
Waters Xevo TQ-S triple quadrupole instrument using elec-
trospray ionization in positive mode. The separation was 
performed on an Acquity BEH C18 column (50 × 2.1 mm, 
1.7 µ) using a Waters Acquity UPLC system with 0.6 mL/
min flow rate and gradient elution. Mobile phase A was 0.1% 
formic acid in water, and B was 0.1% formic acid in ace-
tonitrile (ACN). The column temperature was maintained 
at 60 °C. The calibration standards and quality control (QC) 
samples were prepared in the control blank mouse plasma 
and tissue homogenate. Tissues were homogenized with 3 
or 6 volumes (v/w) of deionized water on the day of analy-
sis. Proteins were precipitated from 10 µL plasma or 5 µL 
tissue homogenate with 200 µL ACN containing 100 ng/
mL Tolbutamide as internal standard in 96-well plates. The 
mixture was vortexed for 2 min and centrifuged at 4000 rpm 
for 30 min at 4 °C. An aliquot of 150 µL supernatant was 
transferred to a 350-µL 96-well plate. 0.2 µL supernatant 
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was injected for the UPLC–MS/MS analysis. Data were ana-
lyzed using MassLynx V4.1.
Lower limit of quantitation (LLOQ), accuracy 
and precision
Bioanalytical method validation was performed in mouse 
plasma and mouse liver. The linear calibration range 
for metarrestin was 1.0–1000  ng/mL for plasma and 
5.0–20,000 ng/g for liver homogenate. The lower limit 
of quantitation of the assay was 1.0 ng/mL in plasma and 
5.0 ng/g in liver homogenate. The accuracy of calibration 
standards was between within 8% of the nominal values. 
Intra-assay variance and deviation from nominal values were 
calculated at low quality-control (LOQ, 1.0 ng/mL plasma 
and 5.0 ng/g liver), middle quality-control (MQC, 10.0 ng/
mL and 500 ng/g), and high quality-control (HQC, 1000 ng/
mL and 20,000 ng/g) levels for six replicates, each of the 
same analytical run (Suppl. Tables 1, 2). The variance of 
the QC samples (CV%, n = 3) ranged from 1.0 to 5.1% and 
the deviation was between 3 and 6% from nominal values. 
No endogenous interference was found at the retention time 
for metarrestin and internal standard as verified by testing 
control blank plasma and liver homogenate. Metarrestin was 
stable in mouse plasma after three freeze-thaw cycles.
Pharmacokinetics calculation
The pharmacokinetic parameters were calculated using the 
non-compartmental approach (Models 200 and 201) of the 
pharmacokinetic software Phoenix WinNonlin, version 6.4 
(Certara, St. Louis, MO). The area under the plasma con-
centration vs time curve (AUC) was calculated using the 
linear trapezoidal method. The slope of the apparent termi-
nal phase was estimated by log linear regression using at 
least three data points and the terminal rate constant (λ) was 
derived from the slope. AUC 0–∞ was estimated as the sum 
of the AUC 0–t (where t is the time of the last measurable 
concentration) and Ct/λ. The apparent terminal half-life (t½) 
was calculated as 0.693/λ.
BODIPY®‑metarrestin microscopy
The PNC disassembly assay has been previously described. 
For the detection of intracellular metarrestin, PC3M cells 
were cultured overnight at 37 °C in 5%  CO2 in 384-well 
black clear bottom low-base plates (Cat# 4518; Corning, 
NY) at the density of 3000 cells/well in 30 µL/well DMEM 
supplemented with 10% FBS and 1% penicillin/streptomy-
cin. 30 µL of a  BODIPY®-labeled analog metarrestin, that 
was able to disassemble PNC in PC3M (PTB-GFP) cells 
expressing green fluorescent protein (GFP)-tagged polypy-
rimidine tract-binding protein 1 (PTB1) (described in [13]) 
at an  IC50 3.32 μM, was added at a final concentration of 
5 µM metarrestin to each well and incubated at 37 °C in 
5%  CO2 for an additional 24 h. Cells were fixed with 4% 
for 10 min at room temperature. Fixed cells were washed 
with PBS containing 0.05% Tween-20 (PBS-T) for 30 min, 
incubated for 15 min at room temperature in 30 µL of 1 µg/
mL Hoechst 33342 (Life Technologies, Carlsbad, CA) to 
visualize cell nuclei, then washed three times with PBS-T for 
5 min per wash, and placed in 30 µL of PBS prior to micros-
copy. Confocal images were obtained using Opera Phoenix 
(PerkinElmer, Waltham, MA) and a 20× objective lens.
Metarrestin metabolites
Hepatocytes monolayers from CD-1 mouse and SD rat, 
at a density of 1 million cells/mL, were incubated 10 µM 
metarrestin at 37 °C for 4 h under 5%  CO2. Metabolic reac-
tions were stopped by adding three volumes of acetonitrile 
(ACN) to the reaction mixture; the samples vortexed and 
centrifuged to precipitate the proteins. The supernatants 
were transferred to clean tubes for drying under a stream 
of nitrogen. The dried residues were reconstituted with 
30% aqueous ACN and aliquots were injected onto LC/
UV/MS system for metabolite ID and profiling. The LC/
UV/MS system was Agilent 1100 HPLC (pumps, autosa-
mpler and PDA) interfaced to a Linear Trap Quadrupole 
(LTQ) ion trap mass spectrometer (ThermoFinnigan) with 
HPLC column: Luna C18(2) column, 250 × 2.0 mm, 5 µM. 
The HPLC mobile phase was a gradient between solvent A 
(0.05% TFA in water) and B (0.05% TFA in ACN) at a flow 
rate of 300 μL/min. At times 0, 2, 25, 28, 30, 31, 40 min the 
ratios of A:B were 95:5, 95:5, 35:65, 5:95, 5:95, 95:5, 95:5 
respectively. The LTQ Mass Spectrometer ran a full scan 
for m/z 250–2000 and data dependent  MSn (n = 4) analysis.
RNA‑seq analysis
Pancreas cancer tissues samples or adjacent, uninvolved 
normal pancreas from vehicle or metarrestin-treated KPC 
animals collected at 0, 3, and 9 h after last dose of 25 mg/
kg metarrestin were homogenized in PureLink Lysis 
Buffer (PureLink RNA Mini Kit, ThermoFisher Scientific 
Waltham, MA) at 4 °C using a TissueLyser II bead mill 
(Qiagen, Valencia, CA, manufactured by Retsch, Newtown, 
PA). Total RNA was isolated using the Life Technologies 
PureLink® RNA Mini Kit, quantified on a NanoDrop 1000 
spectrophotometer (ThermoFisher Scientific, Waltham, 
MA). RNA Integrity Numbers (RIN) obtained on an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA) ranged in tumor RNA preps from RIN 8.9 to 9.7 while 
non-tumor pancreas RIN ranged from 5.6 to 6.8.
Total RNA libraries were prepared using the Illumina 
TruSeq® Stranded Total RNA LT (with Ribo-Zero™Human/
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Mouse/Rat) kit according the manufacturer’s instructions. 
Double-stranded cDNA was purified using AMPure XP 
beads (Beckman Coulter Life Sciences, Indianapolis, IN), 
Sequencing was done using Illumina TruSeq V4 chemistry 
at 2 × 126 cycles on Illumina HiSeq2500. Image file process-
ing to fastq output was done using Illumina HiSeq Real Time 
Analysis version RTA1.18.64 and Bcl2fastq2 version 2.17. 
Sequencing output ranged from 89 to 132 million reads per 
sample. Adapter trimming and base filtering was done using 
Trimmomatic software version 0.3, and the trimmed reads 
were aligned to mouse reference genome (GRCm38/mm10) 
and Ensembl annotation (version 70) using TopHat2 version 
2.0.8. The list of identified differentially expressed genes 
was filtered by excluding transcripts with ≥ twofold change 
in metarrestin-treated vs untreated normal pancreas (to 
select targets with gene expression changes specifically in 
PNC-containing pancreatic tumors but not in PNC-lacking 
normal pancreas), and by preferentially selecting transcripts 
which showed ‘normalization’ of dysregulated gene expres-
sion levels in KPC tumors towards physiologic expression 
levels observed in normal pancreas using the following crite-
ria: tumor treated with metarrestin (tm) vs tumor vehicle (tv) 
abs(fold change) ≥ 3, pancreas treated metarrestin (pm) vs 
pancreas vehicle (pv) absolute(foldChange) < 2, the product 
of the fold change of (tm vs tv) and (pv vs tv) was greater 
than 9.
qRT‑PCR
A total of 450 ng of total RNA was used for single-strand 
complementary DNA synthesis using a SuperScript III First-
Strand kit (Invitrogen, Carlsbad, CA). Complementary DNA 
was amplified using the oligo dT20 (Invitrogen-Life Tech-
nologies) primer supplied in the kit. Reaction products were 
read in a Bio-Rad CFX96 Touch real-time PCR detection 
system (Bio-Rad Laboratories, Hercules, CA).
Results
Pharmacokinetics in wild‑type and tumor‑bearing 
KPC mice
PK in C57BL/6 mice after single IV and PO administration
Following single IV administration of 3 mg/kg in C57BL/6 
mice, the plasma clearance of metarrestin was 48 mL/min/kg 
(Table 1). The steady-state volume of distribution  (Vdss) was 
17 L/kg, indicating that the drug was distributed extensively 
in the body. This was confirmed by the high tissue concen-
trations, determined after oral administration (Table 1; 
Fig. 1). The terminal half-life (t1/2) was ~ 5 h. Following 
single oral administration of 3 and 10 mg/kg via gavage in 
C57BL/6, the absorption of the drug was very good with 
oral bioavailability > 80%. The maximum concentration 
(Cmax) in plasma, observed at 2 h after oral administration, 
was 55.7 ng/mL for the 3 mg/kg treatment and 349 ng/mL 
for the 10 mg/kg treatment, respectively. The corresponding 
AUC 0–∞ values for 3 and 10 mg/kg treatment groups were 
871 and 4790 ng h/mL. The t1/2 for the oral treatment was 
similar to that after IV treatment. Metarrestin concentrations 
in the liver were significantly higher than in the plasma, and 
the AUC ratio of liver/plasma was greater than 50 for both 
orally treated groups (Table 1).
PK in KPC mice after single or multiple PO dose treatments
Following single oral administration of 25 mg/kg via gavage 
in KPC mice, Cmax and AUC 0–∞ in the plasma were 810 ng/
mL and 14,400 ng h/mL, respectively (Table 2; Fig. 2). The 
Tmax was observed at 6 h after drug administration, suggest-
ing a prolonged absorption at a high dose of 25 mg/kg. The 
t1/2 of 8.5 h was also longer than 5–5.6 h observed at low 
doses of 3 and 10 mg/kg in C57BL/6 mice (Tables 1, 2). 
Nevertheless, in vivo systemic exposures (Cmax and AUC 
0–∞) of metarrestin appeared to increase with the dose pro-
portionally from 3 to 25 mg/kg (Fig. 3a, b) after single oral 
administration (3 and 10 mg/kg PO from C57BL/6 mice and 
25 mg/kg PO from KPC mice).
Similar to the initial observations in wild-type mice, 
metarrestin concentrations in KPC mice were higher in 
solid tissues than in plasma, and the AUC 0–24h ratio of tis-
sue/plasma was 19 for tumor, 33 for spleen and 44 for liver 
after single administration of 25 mg/kg metarrestin by PO 
gavage (Table 2). The same high AUC tissue/plasma ratios 
were observed after multiple oral dosing with 25 mg/kg/
day by oral gavage for 14 days (Table 2). On Day 14, the 
AUC 0–24h ratio of tissue/plasma was 37 for tumor, 30 for 
Table 1  Metarrestin pharmacokinetics in C57BL/6 mice after single 
IV and PO administration
NC Not calculated, NA not available
Plasma Plasma Liver Plasma Liver
Dose (mg/kg) 3 3 3 10 10
Route IV PO PO PO PO
AUC 0–24h (ng h/mL) 1010 823 66,100 4520 276,000
AUC 0–∞ (ng h/mL) 1040 871 68,600 4790 281,000
t1/2 (h) 5 5.4 4.7 5.6 4.1
Tmax (h) NC 2 1 2 2
Cmax (ng/mL) NC 55.7 5420 349 21,400
CLp (mL/min/kg) 48  NA NA NA NA
Vdss (L/kg) 17 NA NA NA NA
AUC 0–∞ ratio (tissue/
plasma)
79 59
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spleen and 31 for liver, respectively, after multiple admin-
istration of 25 mg/kg PO in KPC mice. Compared to Day 
1 (data from SD Study), the mean metarrestin concen-
trations in tumor, spleen and liver were higher after MD 
treatment, suggesting drug accumulation in tissues after 
repeated dosing at this dose level (Table 2; Fig. 2). AUC 0–24h 
MD:AUC 0–24h SD ratio ranged from 1.8 for liver 
(987,000 ng h/g for MD:536,000 ng h/g for SD) to 5.0 for 
tumor (1,150,000 ng h/g for MD:232,000 ng h/g for SD) 
indicating accumulation with additional sequestration in 
Table 2  Metarrestin pharmacokinetics in tumor-bearing KPC mice after 25 mg/kg single or multiple dose treatment via oral gavage (PO)
NC Not calculated, NA not available
Sample matrix Single dose PK (single PO dose at 25 mg/kg) PK on day 14 (multiple PO doses at 25 mg/kg/day)
Plasma Tumor Spleen Liver Plasma Tumor Spleen Liver
AUC 0–24h (ng h/mL) 12,100 232,000 396,000 536,000 31,500 1,150,000 959,000 987,050
AUC 0–48h (ng h/mL) NA NA NA NA 38,400 1,810,000 1,220,000 1,290,000
AUC 0–∞ (ng h/mL) 14,400 NC 495,000 653,000 39,300 2,090,000 1,250,000 1,350,000
t1/2 (h) 8.5 NC 9.7 9 8.2 18 8.2 9.6
Tmax (h) 6 6 6 6 3 6 6 6
Cmax (ng/mL) 810 14,000 25,000 34,200 2000 65,000 62,400 59,500
AUC 0–24h ratio (tissue/plasma) 19 33 44 37 30 31
Plasma
Time (hr)










Single Dose, Day 1
Multiple Dose, Day 14
Tumor
Time (hr)










Single Dose, Day 1
Multiple Dose, Day 14
Spleen
Time (hr)









Single Dose, Day 1
Multiple Dose, Day 14
Liver
Time (hr)










Single Dose, Day 1
Multiple Dose, Day 14
Fig. 2  Days 1 and 14 mean (± S.D.) metarrestin concentration–time profiles in tumor-bearing KPC mice after single oral dose of 25 mg/kg or 
multiple oral doses of 25 mg/kg/day (n = 3 per time point)
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tumors (Table 2). Daily dose metarrestin administration at 
25 mg/kg by oral gavage for 14 days was not associated 
with any change in body weight, hypoactivity, or change in 
liver function tests compared to control animals treated with 
vehicle (Suppl. Table 3).
Steady-state intratumor PK in KPC mice
Intratumor metarrestin exposure levels were determined at 
steady-state with continuous administration of metarrestin. 
Previous anti-metastasis and survival studies in mice have 
identified a dose range of 10–25 mg/kg given either by PO 
gavage, or as drug-infused chow as dose levels associated 
with anti-tumor efficacy [15]. When dosed at 3 and 5 mg/kg 
PO, plasma concentrations of metarrestin measured lower 
than the  IC50 values (~ 0.4 µM) determined in cell-based 
assays to effectively suppress PNC and achieve target inhi-
bition. At 10 mg/kg PO single dose administration plasma 
concentrations remained above the  IC50 for > 10 h. Thus, 
we chose a 10 mg/kg dose level which is sufficient to effec-
tively suppress metastasis and extend survival [15]. KPC 
mice were fed with metarrestin-infused chow (70 ppm) 
for 10 days. On Day 10, plasma and tissues were collected 
from three mice every 3 h over a 24 h period while animals 
were maintained on the same metarrestin-containing diet. 
While metarrestin concentration in the plasma remained at 
or below the  IC50, intratumor concentration exceeded the 
cell-based  IC50 by ~ tenfold (Fig. 3c; Suppl. Table 4). The 
mean concentration (Cmean; calculated by AUC 0–24h/24 h) 
was 0.2 µM for plasma, 4.0 µM for tumor, 4.5 µM for spleen 
and 6.4 µM for liver, respectively. The tissue/plasma ratio 
was > 20 for all three tissues (Suppl. Table 5). Thus, intra-
tumor concentration sufficient to achieve target inhibition, 
metastasis suppression and therapeutic response (prolonged 
survival) can be obtained using a solid formulation of metar-
restin. It is also noticed that while Cmax is generally lower 
when the drug is administrated in food chow compared to 
that after oral gavage, the plasma AUC 0–24h at steady-state 
from the metarrestin-chow treated PNC mice appears to be 
comparable to that when the drug is administered via single 
oral gavage at the same dose (4160 ng h/mL from steady-




To establish a dose–response relationship between intratu-
mor exposure levels of metarrestin and mechanism of action 
of the drug in vivo, we first confirmed the ability of metar-
restin to suppress PNC structures in murine pancreatic KPC 
tumors. The prevalence of PNC bodies (expressed as the 
fraction of cells containing one or more PNCs) was 38.2% 
Fig. 3  Administered dose levels (from 3 to 25  mg/kg) and plasma 
exposure of metarrestin are linearly correlated. a AUC 0–24h, and b 
Cmax vs dose plots for single dose PK studies in C57BL/6 and KPC 
mice (R2 regression coefficient). c Day 10 mean (± SD) metarrestin 
concentration–time profiles in tumor-bearing KPC mice after oral 
administration of metarrestin infused food chow (target dose 10 mg/
kg/day; n = 3 per time point)
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in untreated murine KPC tumors (Fig. 4a) which was similar 
to the PNC prevalence in the previously examined NOD/IL2 
gamma (null) PANC1 metastasis model (35.1%) and higher 
than in cancer cell lines derived from primary pancreatic 
tumors (average ~ 23.5%) [15]. After 14-day treatment with 
25 mg/kg metarrestin by oral gavage, PNC prevalence in 
KPC tumors was reduced to 9.8% (Fig. 4b).
To examine whether measured intratumor metarrestin 
concentrations measured in PK studies track with intracellu-
lar metarrestin concentration, we first decided to synthesize 
a fluorophore conjugated analog of metarrestin. Structure 
activity relationship studies around the structure of metarres-
tin were conducted in a high throughput assay that measured 
in dose dependence the ability of compounds to reducing 
Fig. 4  Intratumor metarrestin exposure correlates with PNC preva-
lence and mRNA expression levels of transcriptional regulators 
FOXA1 and FOXO6. a Metarrestin disassembles the peri-nucleolar 
compartment (PNC) in KPC tumors. PNC structures in murine pan-
creas cancer KPC tumors visualized by immunofluorescence with 
α-PTB1 antibodies in tumors from vehicle-treated KPC mice (top 
panels) and from mice treated with 25 mg/kg metarrestin by PO gav-
age for 14 days (bottom panels). Representative images of individual 
tumors are shown; scale bar = 1 µm. b Quantification of PNC preva-
lence in 100 tumor cells in confirmed tumor areas of four tumors per 
treatment (*p < 0.05, **p < 0.01, ***p < 0.001; 2-tailed student’s t 
test). c 20× confocal images of PC3M cells following a 24-h incuba-
tion with 5 µM BODIPY®-labeled analog of metarrestin. Blue: Hoe-
chst/Green: BODIPY®. d UPLC–MS/MS measurement of cellular 
metarrestin concentration in P3CM and KPC cells after treatment 
with 1  µM metarrestin (blue; left) and 10  µM (red; right) (in tripli-
cates; error bars = S.D.; x-axis depicts time in min). e Correlation of 
expression levels of FOXA1 and FOXO6 with intratumor metarres-
tin exposure derived from different KPC cohorts. Relative expression 
levels of FOXA1 and FOXO6 determined by qRT-PCR and normal-
ized to reference genes. FOXA1: mice dosed with vehicle, 25 mg/kg 
PO chow MD (AUC 0–24h 396,000 h ng/mL), and 25 mg/kg PO gavage 
MD (AUC 0–24h 1,150,000 h ng/mL). FOXO6: mice dosed with vehi-
cle, 10  mg/kg PO chow (AUC 0–24h 80,600  h  ng/mL) and 10  mg/kg 
PO steady-state chow (AUC 0–24h 96,100 h ng/mL). N ≥ 4 tumors per 
group, 2-tailed R2 correlation coefficient test. f qRT-PCR of FOXA1 
and FOXO6 in murine and human pancreas cancer cells (see “Meth-
ods”) exposed for 24  h to increasing concentrations of metarrestin 
(n ≥ 2, in triplicates)
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PNC prevalence in PC3M cells [13, 14]. This medicinal 
chemistry effort produced an analog NCGC00244845 (PNC 
 IC50 = 0.089 μM) that was more potent than metarrestin 
(PNC  IC50 = 0.397 μM). This analog was chemically conju-
gated to the fluorophore boron-dipyrromethene (BODIPY®) 
to track the disassembly of the PNC in PC3M cancer cells 
by confocal microscopy (Suppl. Figure 2). The BODIPY-
labelled analog of metarrestin (NCGC00387350) was able to 
disassemble PNC with  IC50 = 3.317 μM in PC3M cells. Con-
focal microscopy showed homogenous intracellular accu-
mulation of the drug in the cytosol (Fig. 4c). Next, to exam-
ine cellular metarrestin levels in relation to extracellular 
concentrations, we exposed KPC and PC3M cells at 1 and 
10 µM concentrations of metarrestin and harvested cells at 
different timepoints. Consistent with the lipophilic nature of 
metarrestin, cellular levels of metarrestin reached 40–100% 
of media concentrations within 40 min (Fig. 4d). The homo-
geneous intracellular distribution of labeled metarrestin in 
cancerous cells, together with its ability to disassemble the 
PNC and a rapid equilibrium between media concentrations 
and cellular metarrestin levels in cancer cells harvested after 
short exposure to metarrestin-containing media suggest that 
measured intratumoral metarrestin concentrations correlate 
with intracellular metarrestin levels effective to disassemble 
the PNC.
To investigate whether the metabolite(s) of metarrestin 
contribute to the activity of the drug, we incubated hepato-
cytes from CD1-mice and SD rats with metarrestin for 4 h 
and analyzed the intracellular (cell lysate) and extracellu-
lar (media supernatant) fraction by HLPC. Three metabo-
lites, that appeared to be products of oxidation via MS/MS 
analysis, were detected at very low (< 5%) concentrations 
compared to the parent metarrestin (Suppl. Figure 3). The 
main metabolite with (M + H)+ = 473 in mouse plasma, after 
MS/MS analysis, was proposed to be the ketone derivative 
of metarrestin, derived via the oxidation of the secondary 
alcohol on metarrestin (Suppl. Figure 4). Keto-metarrestin 
was synthesized and shown in direct comparison to metar-
restin to be equipotent to metarrestin with respect to PNC 
disassembly in PC3M cells (Suppl. Figures 5, 6). Both, the 
low abundance of any metarrestin metabolites, as well as 
the absence of any increased activity of the main metabolite 
appear to indicate that metabolite(s) are not responsible for 
much of the therapeutic action of parent metarrestin.
To arrive at markers driven by metarrestin exposure, 
we next subjected untreated and metarrestin-treated KPC 
tumors and matched normal pancreata to unbiased gene 
expression profiling using RNA-sEq. To hone in on differ-
entially expressed genes selectively induced by metarrestin, 
we first ruled out increased cleaved caspase expression levels 
by immunohistochemistry in treated tumors and pancreata 
to exclude any measure of cytotoxic off-target effects by the 
drug observed at higher concentrations in cell-based assays 
(Suppl. Figure 7). From the 364 transcripts with ≥ three-
fold change in treated vs untreated KPC tumors, we used a 
selection algorithm (see Methods) to identify 18 transcripts 
that were significantly changed (p value < 0.001) specifically 
in metarrestin-treated KPC tumors (Suppl. Figure 8). Two 
of the transcripts, FOXA1 (known for its upregulation and 
pro-metastatic action in pancreatic cancer) and the puta-
tive tumor suppressor FOXO6, [35–37] showed metarres-
tin exposure-dependent expression changes in KPC tumors 
(Fig.  4c) and in cultured mouse and human pancreatic 
cancer cell lines (Fig. 4d). Thus, FOXA1 and FOXO6 may 
provide leads for future predictive biomarker development, 
assist in determination of the minimally efficacious dose, 
and add additional insight into the mechanism of action of 
metarrestin.
Discussion
In this study, we define the PK and PK/PD relationship of 
metarrestin (ML-246) in the plasma, healthy tissues, and 
pancreatic tumors of wild-type and KPC (transgenic Ras-
driven Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ pancreas 
cancer model) mice. Metarrestin is a pyrrolo-pyrimidin 
derivative [trans-4-(7-benzyl-4-imino-5,6-diphenyl-4,7-di-
hydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl) cyclohexanol] able 
to disassemble the peri-nucleolar complex (PNC) without 
geno- or cytotoxicity [13, 14]. It was developed under the 
premise that the PNC is highly correlated with the metastatic 
phenotype in solid organ cancers based on several series of 
well-annotated clinical specimens [7, 11]. The compound 
exerts a novel mechanism of action by targeting isoform 2 
of the translation elongation factor eEF1A (eEF1A2), which 
is a putative oncogene that has been shown to be upregu-
lated in pancreatic and other cancers with expression levels 
that are inversely correlated with clinical outcome [16–20]. 
While phenocopy experiments via silencing or overexpress-
ing eEF1A2 have linked metarrestin’s molecular target to 
PNC prevalence and metastasis formation in vivo, the exact 
impact of metarrestin on the pleiotropic molecular functions 
of eEF1A2 is still to be elucidated [15, 21]. It is likely that 
at concentrations sufficient to disassemble the PNC, metar-
restin is also affecting non-canonical functions of eEF1A2 
such as regulation of proteolysis, nuclear transport, oxidative 
stress, or regulation of gene transcription [23, 38]. Here, we 
establish that disassembly of the PNC and therapeutic effi-
cacy (suppression of metastasis and extension of survival in 
the NSG luc[GLP] Panc1 metastasis model) can be achieved 
at 10 mg/kg dosing with solid or liquid formulations of 
metarrestin. These dose levels achieve intratumor AUC 
levels of > 80,000 ng h/mL and translate into single-digit 
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micromolar (µmol/kg) metarrestin concentrations in tumors 
(Fig. 3) maintained for over 24 h from dosing. Such intra-
tumor drug levels are particularly desirable in pancreatic 
cancer where the dense desmoplastic stroma and abnormal 
vasculature impede drug delivery. For this study, we chose 
the well-validated autochthonous KPC model which has 
been shown to recapitulate the unique cytoarchitectural, vas-
cular, and microenvironmental biology of human pancreas 
cancer better than heterotopic or orthotopic xenotransplanta-
tion models [28].
One of the initial findings on the pharmacokinetic behav-
ior of metarrestin elucidated within this study is the large 
volume of distribution, moderate clearance, and accumula-
tion of the drug upon multiple dosing. After 14-day daily 
dosing with 25 mg/kg by PO gavage, metarrestin exposure 
(AUC 0–24h) was about twofold higher in plasma and liver and 
nearly fivefold higher in pancreatic tumors than in animals 
treated with a single dose. This PK profile is in line with sev-
eral observations reported previously [14]. The high steady-
state drug concentration in tumor tissue (about 10-fold 
higher than the in vitro  IC50) and the relatively long half-life 
suggest that less than daily dosing might be sufficient for 
anti-tumor activity in future preclinical and clinical studies. 
The high bioavailability (≥ 80%) and the Tmax of < 2 h in 
plasma and < 6 h in most tissues indicated that drug is well 
absorbed after oral administration. Metarrestin has high tis-
sue penetration, with AUC tissue:AUC plasma ratio well above 
ten for the majority of solid organs, including pancreatic 
tumors, suggesting that therapeutically efficacious concen-
trations can be achieved even in pancreatic cancers known 
to be refractory for drug penetration and delivery [39]. With 
regard to drug delivery challenges, which are a significant 
hurdle in the development of more effective therapies for 
pancreatic cancer, there are two noteworthy observations on 
the pharmacokinetic behavior of metarrestin. First, the tissue 
distribution of metarrestin was largely independent of blood 
perfusion, as drug levels in poorly-vascularized pancreatic 
tumors were as high or higher as in some highly perfused 
solid organs. This suggests that therapeutically effective 
doses could be achieved in tumors without excessive toxic-
ity in highly perfused organs. Second, there appears to be a 
retention effect of metarrestin in tumors compared to other 
solid organs. It is tempting to speculate that the abundance 
of the translation elongation factor A2 (eEF1A2), the molec-
ular target of metarrestin which can comprise up to 1% of the 
total protein in cancer cells, accounts for the prolonged half 
life and increased AUC measures of intratumoral metarrestin 
compared to other organs. The sequestering of anti-cancer 
drugs via binding to components overexpressed in pancreatic 
tumors to overcome the poor drug delivery has recently gar-
nered significant interest in the field through the introduction 
of nab-paclitaxel in combination with gemcitabine into clini-
cal practice; paclitaxel bound to albumin (nab-paclitaxel, 
Abraxane®) binds via its albumin component to secreted 
protein acidic and rich in cysteine (SPARC) a stromal matrix 
protein overexpressed in many pancreatic and breast can-
cers and intratumoral paclitaxel levels correlate with tumoral 
SPARC expression levels [40, 41].
Previous in vitro studies showed that the PNC is restored, 
the nucleolus is reorganized, and cell proliferation recov-
ers after removal of metarrestin, suggesting that the drug 
acts via a cytostatic mechanism [14, 15]. Thus, it may be 
especially important to continuously maintain metarrestin 
exposure at a therapeutically effective level, but findings 
from this study and our previous report suggest that this can 
be readily achieved in tumors without detectable toxicity in 
healthy tissues [15]. Using RNA-seq gene expression profil-
ing, we identified 18 transcripts as candidate metarrestin PD 
markers, which are restored to normal pancreas expression 
level after metarrestin treatment. These include the metas-
tasis enhancer FOXA1 and the putative tumor suppressor 
FOXO6. Interestingly, the known role of FOXA1 in the meta-
static transition of pancreas cancer, originally identified in 
the KPC animal model used in this study, and the tumor 
suppressor functions of FOXO6 in lung cancer cells provide 
biologically plausible links to the anti-metastatic phenotype 
of metarrestin [35–37].
In summary, here we report a comprehensive PK profile 
of metarrestin in wild-type and tumor-bearing KPC mice. 
The PK properties described here, including high oral bio-
availability, a large volume of distribution, relatively long 
half-life, and moderate clearance with accumulation in 
tumor tissues will inform the design of future preclinical 
and IND enabling studies. The excellent tissue penetration 
of metarrestin and the absence of detectable toxicity make 
metarrestin an attractive therapeutic candidate for future 
development, in particular, in tumor types with dense des-
moplastic stroma and poor drug delivery.
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